Log in to save to my catalogue

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalenc...

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalenc...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e2e3c987d9e84ccb9b7c66bef2e582d6

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

About this item

Full title

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2020-07, Vol.11 (1), p.3774-3774, Article 3774

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patien...

Alternative Titles

Full title

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e2e3c987d9e84ccb9b7c66bef2e582d6

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e2e3c987d9e84ccb9b7c66bef2e582d6

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-020-17703-6

How to access this item